Intravenous iron: Not just for hemodialysis patients anymore

Peritoneal Dialysis International

Volumn 28, Issue 2, 2008, Pages 126-129

  Wish, Jay B ^a  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANEMIC AGENT; CARBOHYDRATE; ERYTHROPOIETIN; FERRIC CARBOXYMALTOSE; FERRIC HYDROXIDE SUCROSE; FERRITIN; FERROUS GLUCONATE; FERROUS SULFATE; FERUMOXYTOL; IRON DERIVATIVE; IRON DEXTRAN; TRANSFERRIN; UNCLASSIFIED DRUG;

ANAPHYLAXIS; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; DRUG BIOAVAILABILITY; DRUG COST; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG FORMULATION; DRUG MEGADOSE; DRUG SAFETY; FERRITIN BLOOD LEVEL; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; HYPOTENSION; IRON DEFICIENCY ANEMIA; IRON INTAKE; LOW DRUG DOSE; MORBIDITY; MORTALITY; NAUSEA; NOTE; PERITONEAL DIALYSIS; PRIORITY JOURNAL; SINGLE DRUG DOSE; TRANSFERRIN BLOOD LEVEL; UNSPECIFIED SIDE EFFECT; VOMITING;

EID: 42349105597     PISSN: 08968608     EISSN: None     Source Type: Journal    
DOI: 10.1177/089686080802800205     Document Type: Note

References (26)

1. National Kidney Foundation. DOQI Clinical practice guidelines for the treatment of anemia of chronic renal failure. Am J Kidney Dis 1997; 30(Suppl 3):S192-240.
2. Wish JB. Assessing iron status: beyond ferritin and transferrin saturation. Clin J Am Soc Nephrol 2006; 1(Suppl 1): S4-8.
3. National Kidney Foundation. KDOQI Clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. Am J Kidney Dis 2006; 47(Suppl 3):S1-145.
4. Besarab A, Amin N, Ahsan M, Vogel SE, Zazuwa G, Frinak S, et al. Optimization of epoetin therapy with intravenous iron supplementation in hemodialysis patients. J Am Soc Nephrol 2000; 11:530-8.
5. Besarab A, Kaiser JW, Frinak S. A study of parenteral iron regimens in hemodialysis patients. Am J Kidney Dis 1999: 34:21-8.
6. Coyne DW, Kapoian T, Suki W, Singh AK, Moran JE, Dahl NV, et al. Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: results of the Dialysis Patients' Response to IV Iron with Elevated Ferritin (DRIVE) Study. J Am Soc Nephrol 2007; 18:975-84.
7. Pizzi LT, Patel NM, Maio VM, Goldfarb DS, Michael B, Fuhr JP, et al. Economic implications of non-adherence to treatment recommendations for hemodialysis patients with anemia. Dial Transplant 2006; 35:660-71.
8. National Kidney Foundation. K/DOQI Clinical practice guidelines for anemia of chronic kidney disease: update 2000. Am J Kidney Dis 2001; 37(Suppl 1):S182-238.
9. Hakim RM, Stivelman JC, Schulman G, Fosburg M, Wolfe L, Imber MJ, et al. Iron overload and mobilization in longterm hemodialysis patients. Am J Kidney Dis 1987; 10: 293-9.
10. Ali M, Fayemi AO, Rigolosi R, Frascino J, Marsden T, Malcolm D. Hemosiderosis in hemodialysis patients. An autopsy study of 50 cases. JAMA 1980; 244:343-5.
11. Morrison ED, Brandhagen DJ, Phatak PD, Barton JC, Krawitt EL, El-Serag HB, et al. Serum ferritin Level predicts advanced hepatic fibrosis among U.S. patients with phenotypic hemochromatosis. Ann Intern Med 2003; 138: 627-33.
12. Bishu K, Agarwal R. Acute injury with intravenous iron and concerns regarding long-term safety. Clin J Am Soc Nephrol 2006; 1(Suppl 1):S19-23.
13. Kalantar-Zadeh K, Regidor DL, McAllister CJ, Michael B, Warnock DG. Time-dependent associations between iron and mortality in hemodialysis patients. J Am Soc Nephrol 2005; 16:3070-80.
14. Hoen B, Paul-Dauphin A, Hestin D, Kessler M. EPIBACDIAL: a multicenter prospective study of risk factors for bacteremia in chronic hemodialysis patients. J Am Soc Nephrol 1998; 9:869-76.
15. Li H, Wang S. Intravenous iron sucrose in peritoneal dialysis patients with renal anemia. Perit Dial Int 2008; 28: 149-54.
16. Besarab A, Coyne D, Bolton WK, Sharma A, Foti A, Brenner L. Ferumoxytol as an intravenous iron replacement therapy: safety results from two phase III studies in subjects with chronic kidney disease [Abstract]. J Am Soc Nephrol 2007; 18:762A.
17. Spinowitz B, Kausz A, Miller P, Brenner L, Singh A. Achievement of target hemoglobin with ferumoxytol versus oral iron in anemic CKD patients [Abstract]. J Am Soc Nephrol 2007; 18:814A.
18. Singh A, Spinowitz B, Provenzano R, Bolton WK, Baptista J, Pereira B. Safety of ferumoxytol as intravenous (IV) iron therapy for iron deficiency anemia [Abstract]. J Am Soc Nephrol 2007; 18:291A.
19. Bolton WK, Besarab A, Germain M, Kovesdy CP, Hutchinson J, Kausz A. Ferumoxytolas an IV iron replacement therapy: efficacy results from two phase III studies in patients with chronic kidney disease (CKD) [Abstract]. J Am Soc Nephrol 2007; 18:761A.
20. Quinibi W, Dinh O, Benjamin J. Safety and tolerability profile of ferric carboxymaltose (FCM), a new high dose intravenous iron, across ten multi-center clinical trials [Abstract]. J Am Soc Nephrol 2007; 18:813A-814A.
21. Quinibi W, Martinez C, Smith M, Benjamin J, Dinh Q. A randomized controlled trial comparing IV ferric carboxy-maltose (FCM) to oral iron in anemic patients with non dialysis-dependent CKD [Abstract]. J Am Soc Nephrol 2007; 18:814A.
22. Besarab A. Resolving the paradigm crisis in intravenous iron and erythropoietin management. Kidney Int Suppl 2006; 101:S13-18.
23. Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1998; 339:584-90.
24. Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006; 355:2085-98.
25. General Accounting Office. End stage renal disease. Medicare payments for all ESRD services, including injectable drugs, should be bundled. Washington, DC: US Government Accountability Office; 2006: publication GAO-07-266T.
26. Wish JB. The economic realities of erythropoiesis-stimulating agent therapy in kidney disease. Kidney Int Suppl 2006; 104:S21-5.